BHLHE41: A Potential Drug Target and Biomarker (G79365)

Target Name: BHLHE41

NCBI ID: G79365

BHLHE41

BHLHE41: A Potential Drug Target and Biomarker

BHLHE41 (SHARP-1) is a gene that has been identified as a potential drug target and biomarker for various diseases, including cancer. The gene is located on chromosome 6 and encodes a protein known as BHLHE41. BHLHE41 is a transcription factor, which means it plays a role in regulating gene expression.

Studies have shown that BHLHE41 is involved in many different processes in the body, including cell growth, differentiation, and apoptosis (programmed cell death). It has also been shown to be involved in the development and progression of various diseases, including cancer.

One of the key reasons for the interest in BHLHE41 is its potential as a drug target. By interacting with this gene, researchers can potentially develop new treatments for a variety of diseases. For example, if BHLHE41 is shown to be involved in the development of cancer, researchers may be able to develop new treatments for this disease.

In addition to its potential as a drug target, BHLHE41 has also been shown as a potential biomarker. By analyzing the levels of BHLHE41 in different tissues and fluids, researchers can potentially monitor the effectiveness of treatments for various diseases. For example, if a treatment is shown to be effective in reducing the levels of BHLHE41 in cancer cells, this may be a sign that the treatment is working.

Another study also suggested that BHLHE41 may be a potential target for cancer immunotherapy. The authors of the study found that BHLHE41 was expressed in various tissues and fluids, including the blood, lymph nodes, and brain, which suggests that it may be a potential target for cancer immunotherapy.

Overall, BHLHE41 is a gene that has the potential to be a drug target and biomarker for various diseases. Further research is needed to fully understand its role in the body and its potential as a treatment.

Protein Name: Basic Helix-loop-helix Family Member E41

Functions: Transcriptional repressor involved in the regulation of the circadian rhythm by negatively regulating the activity of the clock genes and clock-controlled genes (PubMed:11278948, PubMed:14672706, PubMed:15193144, PubMed:15560782, PubMed:18411297, PubMed:19786558, PubMed:25083013). Acts as the negative limb of a novel autoregulatory feedback loop (DEC loop) which differs from the one formed by the PER and CRY transcriptional repressors (PER/CRY loop). Both these loops are interlocked as it represses the expression of PER1 and in turn is repressed by PER1/2 and CRY1/2. Represses the activity of the circadian transcriptional activator: CLOCK-BMAL1 heterodimer by competing for the binding to E-box elements (5'-CACGTG-3') found within the promoters of its target genes (PubMed:25083013). Negatively regulates its own expression and the expression of DBP and BHLHE41/DEC2. Acts as a corepressor of RXR and the RXR-LXR heterodimers and represses the ligand-induced RXRA/B/G, NR1H3/LXRA, NR1H4 and VDR transactivation activity. Inhibits HNF1A-mediated transactivation of CYP1A2, CYP2E1 AND CYP3A11 (By similarity)

The "BHLHE41 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BHLHE41 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets